- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, October 4, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A newsletter from NYU Langone Health referenced a video interview published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The interview, “Amivantamab Presents an Exciting Treatment Opportunity in NSCLC,” featured an interview with Joshua K. Sabari, MD, to speak about the 2 FDA approvals for amivantamab to treat non–small cell lung cancer.
An article from Becker’s GI & Endoscopy referenced an article published on AJMC.com. The article, “Updated Colonoscopy Guidelines Have Implications on Doctors, Patients Alike,” featured interviews with the coauthor of the American College of Gastroenterology and American Society for Gastrointestinal Endoscopy colonoscopy guidelines as well as a doctor from Vanderbilt University Medical Center to discuss the implications of the new guidelines and what to expect once they are implemented.
An article from Pharmacy Times referenced an article published AJMC’s sister site, The Center for Biosimilars®. The article, “FDA Approves First Stelara Biosimilar,” reported on the FDA approval of ustekinumab-auub to treat moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn disease, and moderately to severely active ulcerative colitis.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
